Cellegy Fortigel “not approvable”
Executive Summary
Cellegy plans to meet with FDA in "next month or so" to discuss agency concerns about elevated serum testosterone levels associated with Fortigel. FDA issued "not approvable" letter for testosterone gel citing "insufficient information" in NDA to demonstrate that "high supraphysiologic daily Cmax serum testosterone levels achieved in a significant portion of participants" in clinical trials "are safe under conditions of chronic administration," Cellegy says...
You may also be interested in...
Cellegy regulatory affairs staff changes
Cellegy announces resignation of Senior VP-Medical and Regulatory Affairs Daniel Azarnoff, MD, and VP-Regulatory Affairs and Quality William Schary, MD, Aug. 14. The company will engage the law firm of Hyman, Phelps & McNamara to manage FDA regulatory concerns. New arrangement follows a recent FDA "not approvable" letter for Fortigel (1"The Pink Sheet" July 14, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.